Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6540788 | 1.00 | SIGMAR1 (0.46) | SIGMAR1CYP3A4MAPK1KDM4EMEN1 | |
| SCHEMBL23023068 | 0.90 | SIGMAR1 (0.55) | SIGMAR1CYP3A4MAPK1KDM4EMEN1 | |
| SCHEMBL1823141 | 0.90 | SIGMAR1 (0.55) | SIGMAR1CYP3A4MAPK1KDM4EMEN1 | |
| SCHEMBL7041284 | 0.90 | SIGMAR1 (0.55) | SIGMAR1CYP3A4MAPK1KDM4EMEN1 | |
| SCHEMBL28653629 | 0.85 | SIGMAR1 (0.51) | SIGMAR1CYP3A4MAPK1KDM4EMEN1 | |
| SCHEMBL6487403 | 0.85 | CNR1 (0.56) | SIGMAR1CYP3A4MAPK1KDM4EMEN1 | |
| SCHEMBL6487410 | 0.85 | CNR1 (0.56) | SIGMAR1CYP3A4MAPK1KDM4EMEN1 | |
| SCHEMBL14733411 | 0.85 | SIGMAR1 (0.51) | SIGMAR1CYP3A4MAPK1KDM4EMEN1 | |
| SCHEMBL28653631 | 0.85 | SIGMAR1 (0.51) | SIGMAR1CYP3A4MAPK1KDM4EMEN1 | |
| SCHEMBL10877160 | 0.84 | SMN1; SMN2 (0.51) | SIGMAR1CYP3A4MAPK1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | SIGMAR1 975/4885CYP3A4 4197/4885MAPK1 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.